Evidence map›Paper›PMID 35444232›Full record

Trial reportBone marrow transplantation2022

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.

Sarah Farag, Ulrike Bacher, Barbara Jeker, Myriam Legros, Gaelle Rhyner, Jean-Marc Lüthi, Julian Schardt, Thilo Zander, Michael Daskalakis, Behrouz Mansouri and 2 more

Open access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Rising Prevalence of Low-FrequencyCurrent issues in molecular biology · 2024
    Article
  3. Article
  4. Optimizing high dose melphalan.Blood reviews · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Sarah FaragDepartment of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Ulrike BacherDepartment of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Barbara JekerDepartment of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Myriam LegrosDepartment of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Gaelle RhynerDepartment of Oncology, Cantonal Hospital Fribourg, Fribourg, Switzerland.
Jean-Marc LüthiRegional Hospital Thun, Thun, Switzerland.
Julian SchardtBürgerspital Solothurn, Solothurn, Switzerland.
Thilo ZanderCantonal Hospital Lucerne, Lucerne, Switzerland.ORCID http://orcid.org/0000-0003-3691-7497
Michael DaskalakisDepartment of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-8138-0505
Behrouz MansouriDepartment of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Chantal ManzClinaMed, Therwil, Switzerland.
Thomas PabstDepartment of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland. thomas.pabst@insel.ch.ORCID http://orcid.org/0000-0002-6055-5257
University of Bern · CHFribourg Development Agency · CHSolothurner Spitäler · CHUniversity of Lucerne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Definite cure remains exceptional in myeloma patients even after high-dose chemotherapy (HDCT) with melphalan (Mel) and autologous stem cell transplantation (ASCT). Thus, improving efficacy of HDCT in MM remains an unresolved issue. This randomized phase II trial compared standard 200 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideHumansMelphalanTransplantation, AutologousBendamustine HydrochlorideMelphalan

Identifiers

PMID35444232
PMCPMC9018972
OpenAlexW4224275732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.